Brevan Howard Capital Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Brevan Howard Capital Management’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$363K	Buy	+9,334	New	+$343K	0.84%	26

Other funds holding NDRM

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Allianz Asset Management

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

Brevan Howard Capital Management's NDRM Position: Q3 2017 in Review

Brevan Howard Capital Management opened a new position in NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017: 9,334 shares worth $363K. The stake represents 0.84% of the portfolio and ranks #26 among its holdings.

81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

Brevan Howard Capital Management held 9,334 shares of NeuroDerm Ltd. Ordinary Shares worth $363K as of Q3 2017.
NeuroDerm Ltd. Ordinary Shares was a new Brevan Howard Capital Management position in Q3 2017.
NeuroDerm Ltd. Ordinary Shares made up 0.84% of Brevan Howard Capital Management's portfolio in Q3 2017, its #26 holding.
81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Brevan Howard Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.